Profectus BioSciences to Present at Upcoming Investor Meetings

BALTIMORE--(Business Wire)--
Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical
company focused on the development of novel vaccine candidates for chronic viral
infections announced today that Shawn P. O`Brien, President and Chief Executive
Officer, will present a corporate overview at two leading investor conferences;
BIO National Venture Conference and the 11th Annual C21 BioVentures.

Mr. O`Brien will be available for one-on-one meetings with potential investors
during both conferences:

What:BIO National Venture Conference

When:March 31-April 1, 2009

Where: Boston, MA at the Sheraton Boston Hotel

Presentation: Tuesday, March 31, 2009 from 3:00-3:15 p.m. in the Berkeley room

For more information, please visit http://bnvc.bio.org/opencms/BioVenture/2009/

What: The 11th Annual C21 BioVentures

When: April 7-9, 2009

Where: Napa, CA at the Meritage Resort

Presentation: Thursday, April 9 from 2:00-2:15 p.m. in Salon IV

For more information, please visit http://www.techvision.com/c21/

About Profectus BioSciences Inc.

Profectus Biosciences, is a research and development vaccine company devoted to
advancing the treatment and prevention of chronic viral diseases. The Company`s
first clinical vaccine candidate for human immunodeficiency virus (HIV) is
planned to be tested in clinical trials in 2009. It is expected that data
generated from the series of proof of concept trials will be useful in the
clinical development of vaccine candidates for hepatitis C virus (HCV). The
Profectus proprietary vaccine design approach combines its rVSV and pDNA
platforms via a unique prime boost strategy to advance vaccine research.
Profectus broad pipeline will address (HIV), (HCV), Human Papilloma Virus (HPV)
and Herpes Simplex Virus (HSV).

Profectus has received over $36 million in funding from multiple sources
including National Institutes of Health (NIH), Cross Atlantic Capital Partners
and through private investments. Profectus deploys these resources in support of
its proprietary prime boost vaccines and its anti-inflammatory small molecules
for cancer and chronic viral diseases. For more information, please visit:
http://www.profectusbiosciences.com.

LaVoie Group
Lisa Rivero, 978-745-4200 x106
lrivero@lavoiegroup.com
http://www.lavoiegroup.com

Copyright Business Wire 2009